Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease.
Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease.
复制标题
慢性移植物抗宿主病患者大疱性类天疱疮与抗 CD20 和抗 CD25 抗体的联合治疗。
DOI：
10.1038/sj.bmt.1703654
复制
发表时间：
2002
影响因子：
4.8
通讯作者：
Kurtzberg,J
中科院分区：
文献类型：
--
作者：
Szabolcs,P;Reese,M;Yancey,KB;Hall,RP;Kurtzberg,J
在这个病例中，我们描述了一种新的治疗方法，使用两种针对大疱性类天疱疮(BP)的自身免疫B细胞克隆的嵌合单抗(MOAB)作为激素难治性慢性移植物抗宿主病(GVHD)的表现，这种疾病发生在无关的脐血移植后。通过监测BP特异性循环抗体和表达CD25的活化T淋巴细胞亚群，我们将抗CD20(利妥昔单抗)介导的B细胞消融与抗CD25(Daclizumab)治疗相结合，以阻断CD4+T细胞的帮助。在开始治疗的4周内取得了完全的临床和血清学反应，使全球免疫抑制得以显着减少。
In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.